This company has been marked as potentially delisted and may not be actively trading. Pieris Pharmaceuticals (PIRS) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock PIRS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Pieris Pharmaceuticals IncApril 18, 2025 | money.usnews.comPalvella Therapeutics Inc (PVLA)December 27, 2024 | investing.comMain Line biotech firm completes reverse merger, raises $78.9 millionDecember 17, 2024 | bizjournals.comOne new option listing and one option delisting on December 16thDecember 17, 2024 | markets.businessinsider.comPalvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease TreatmentsDecember 14, 2024 | msn.comPalvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 MillionDecember 14, 2024 | markets.businessinsider.comPIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRSNovember 20, 2024 | businesswire.comPieris Pharmaceuticals announces first patient dosed in SELVA Phase 3 trialNovember 7, 2024 | markets.businessinsider.comAridis Pharmaceuticals (OTC:ARDS) Stock Quotes, Forecast and News SummaryOctober 19, 2024 | benzinga.comPalvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual ConferenceOctober 15, 2024 | globenewswire.comPalvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic MalformationsOctober 3, 2024 | globenewswire.comKubota Pharmaceutical Holdings Co., Ltd. (4596.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comPieris Pharmaceuticals Inc.September 24, 2024 | barrons.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, ENV, AFBI on Behalf of ShareholdersAugust 16, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRSAugust 16, 2024 | prnewswire.comInside the deal: How Palvella Therapeutics plans to go public through a reverse merger with a Boston pharma firmAugust 16, 2024 | bizjournals.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of ShareholdersAugust 16, 2024 | globenewswire.comPIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q2 2024August 15, 2024 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of ShareholdersAugust 14, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRSAugust 13, 2024 | globenewswire.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Purchases 3,000 SharesAugust 13, 2024 | insidertrades.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of ShareholdersJuly 25, 2024 | stockhouse.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.July 24, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public ShareholdersJuly 24, 2024 | prnewswire.comWhy Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?July 24, 2024 | investorplace.comTraders Digest Alphabet, Tesla Results, Fueling Premarket Losses for US Equity FuturesJuly 24, 2024 | msn.comPieris Pharma Shares Double on Buyout Offer From Palvella TherapeuticsJuly 24, 2024 | marketwatch.comPieris Pharma surges on all-stock merger dealJuly 24, 2024 | msn.comPieris Pharmaceuticals, Inc.: Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger AgreementJuly 24, 2024 | finanznachrichten.dePIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q1 2024May 17, 2024 | investorplace.comPieris Pharmaceuticals: Q1 Earnings SnapshotMay 15, 2024 | washingtonpost.comPieris Pharmaceuticals (NASDAQ:PIRS) Shares Gap Down to $12.00April 24, 2024 | marketbeat.comPieris Pharmaceuticals (NASDAQ:PIRS) Sees Large Volume IncreaseApril 23, 2024 | marketbeat.comPieris Pharmaceuticals (Nasdaq:PIRS) HeadlineTrading was temporarily halted for "PIRS" at 07:04 PM with a stated reason of "News pending."...April 23, 2024 | marketbeat.comAvalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72MApril 1, 2024 | msn.comPieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty PotentialMarch 28, 2024 | finanznachrichten.dePieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty PotentialMarch 27, 2024 | finance.yahoo.comPIRS Apr 2024 2.500 callMarch 19, 2024 | finance.yahoo.comPieris Pharmaceuticals Inc (PIRS)February 10, 2024 | investing.comPieris Pharmaceuticals, Inc. (PIRS)February 1, 2024 | finance.yahoo.comInvestors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%December 18, 2023 | finance.yahoo.comPieris Pharmaceuticals Inc (PIRS) Earnings Dates & ReportsNovember 20, 2023 | investing.comPieris Pharmaceuticals Inc PIRSNovember 4, 2023 | morningstar.comMPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's WhySeptember 25, 2023 | finance.yahoo.comIs Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive AnalysisAugust 24, 2023 | finance.yahoo.comPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should KnowAugust 23, 2023 | finance.yahoo.comPieris (PIRS) Up On Receiving Milestone Payment From PartnerAugust 18, 2023 | msn.comPieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology BispecificAugust 17, 2023 | finance.yahoo.comPieris (PIRS) Pursues Strategic Alternatives, Stock RisesJuly 19, 2023 | finance.yahoo.comPieris Pharma Cuts Around 70% Workforce; Plans Strategic OptionsJuly 19, 2023 | markets.businessinsider.com Get Pieris Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PIRS Media Mentions By Week PIRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PIRS News Sentiment▼0.941.05▲Average Medical News Sentiment PIRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PIRS Articles This Week▼00▲PIRS Articles Average Week Get the Latest News and Ratings for PIRS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Pieris Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies BeyondSpring News VolitionRx News Metagenomi News ABVC BioPharma News Artiva Biotherapeutics News Repare Therapeutics News Prelude Therapeutics News Gain Therapeutics News MiNK Therapeutics News Aligos Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PIRS) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pieris Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
